Register
A new injectable drug for treatment of hairy cell leukemia |
Journal Updates
eMediNexus Coverage from: 
A new injectable drug for treatment of hairy cell leukemia
eMediNexus,  14 September 2018
remove_red_eye 644 Views
#Hematology #Oncology

0 Read Comments                

The US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!